SNTI
Senti Biosciences Holdings, Inc.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
Last earnings +8.0% on 2026-05-14
$1.09
▲ +1.87%$1.09▼ -45.23%
over 1Y
L $0.77EODHDH $2.39
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.9%
1W+11.8%
1M+7.9%
3M+38.0%
YTD-0.9%
1Y-45.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Unprofitable (net margin -279263.6%).
Revenue (FY2025) $22.0K · FY2025
Senti Biosciences Holdings, Inc. shows $22.0K in FY2025 revenue, a -279263.6% net margin, and -1099.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.29M | $3.29M | $1.98M | $0.00 | $22.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.4M | -$62.1M | -$92.7M | -$61.0M | -$68.8M |
| Net income | -$55.3M | -$58.2M | -$71.1M | -$52.8M | -$61.4M |
| Diluted EPS | -$19.00 | -$2.23 | -$16.01 | -$12.03 | -$2.73 |
| Net margin | -2414.6% | -1771.5% | -3592.4% | — | -279263.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$17.5M
EV / EBITDA—
EV / Sales796.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-181.0%
FCF yield-128.6%
Quality & risk
ROIC (est.)-972.2%
Free cash flow-$43.6M
Total debt—
Net cash$16.4M
Altman Z-Score-13.57 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+19.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-29). Worth a closer look.
Recent filings
all on EDGAR ↗S-3Filing2026-06-18open ↗DFiling2026-06-04open ↗8-KPeriod ending 2026-05-202026-05-26open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗15-12GFiling2026-05-08open ↗SCHEDULE 13D/AFiling2026-05-04open ↗424B5Filing2026-05-01open ↗8-KPeriod ending 2026-04-272026-05-01open ↗EFFECTFiling2026-04-29open ↗EFFECTFiling2026-04-29open ↗EFFECTFiling2026-04-29open ↗
Frequently asked
- Is Senti Biosciences Holdings, Inc. (SNTI) a buy?
- SNTI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Unprofitable (net margin -279263.6%).
- What is Senti Biosciences Holdings, Inc.'s quality score?
- SNTI scores 25.509803921568626/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001854270, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:05:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.